Tentarix Biotherapeutics, Lp Announces the Formation of a Scientific Advisory Board
Tentarix Biotherapeutics, LP has formed a Scientific Advisory Board (SAB), as well as appointments to its Board of Directors and leadership team. Dr. Thomas F. Bumol – Dr. Bumol joined the Allen Institute as Executive Vice President and Director of the Allen Institute for Immunology after a 35-year career at Lilly. Dr. Brian A. Kuhlman, he is an Oliver Smithies Investigator, a Professor in the Department of Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, and Co-Director of the Molecular and Cellular Biophysics Program. John R. Teijaro, Ph.D., he is an Associate Professor in the Department of Immunology and Microbiology at the Scripps Research Institute in San Diego. Additionally, Brady Johnson was appointed Senior Vice President, Finance and Operations. Mr. Donald Santel – Don served as Executive Chairman of Adicet Bio Inc., a private allogeneic cell therapy oncology company, from October 2017 through its business combination with resTORbio Inc. in September 2020.
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology.
Tentarix Biotherapeutics Emerged with $50 Million Series A funding in October 2021.